Back to journals
Academic Journal

JAMA Psychiatry

27 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 27 psychedelic papers Blossom tracks from JAMA Psychiatry line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does JAMA Psychiatry carry?

Sourced

Tracked papers by publication year; 9 earlier papers published before 2012. Click a year for the running total.

3papers published in 2024

+200% vs 2023

19 published by 2024

Browse papers→

Don't read as the journal's total output: only the 27 of 27 tracked psychedelic papers from JAMA Psychiatry with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does JAMA Psychiatry publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
17
Safety & Risk Management
8
Anxiety Disorders
8
Schizophrenia
8
Suicidality
7
Older Adults
5
Bipolar Disorder
5
Addiction & Substance Use
4
Other
28

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does JAMA Psychiatry cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
11
Psilocybin
8
LSD
6
DMT
4
MDMA
2
5-MeO-DMT
2
Ayahuasca
1
Ibogaine
1
Other
2

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

JAMA Psychiatry has 27 tracked papers indexed in Blossom (1962–2026) from 236 authors, most often covering Ketamine, Psilocybin and LSD, across Depressive Disorders, Major Depressive Disorder (MDD) and Safety & Risk Management.

Published Papers

Paywallmeta

Blinding Integrity in Psychedelic Randomized Clinical Trials A Systematic Review

This systematic review (s=112) examined blinding in psychedelic randomised clinical trials for psychiatric disorders and found that only about a third assessed blinding, while functional unblinding was common, especially in psilocybin, LSD, ayahuasca and MDMA studies. The review found no control strategy that consistently maintained ideal blinding, raising concerns that expectancy effects may bias reported outcomes.

Published
Journal
JAMA Psychiatry
Authors
Orsini, D. K., Wong, S., Di Luch, S., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., Johnson, D. E., Kaczmarek, E. S., Goel, A., Burke, M. J., Mansur, R., McIntyre, R. S., Husain, M. I., Rosenblat, J. D.
Paywallindividual

General Anesthesia and Discrete Components of Ketamine Neurophysiology

This cohort study (n=52) examined how general anaesthesia changes ketamine’s brain activity patterns in healthy volunteers, surgical patients and people with depression. Ketamine given during general anaesthesia kept its beta-gamma effects but lost the usual theta increase, suggesting these neurophysiological components can be separated.

Published
Journal
JAMA Psychiatry
Authors
Deverett, B., Li, D., Lii, T. R., Vlisides, P. E., Tarnal, V., Forsyth, A., Sumner, R., Sikka, P., Schatzberg, A. F., Muthukumaraswamy, S., Mashour, G. A., Heifets, B. D.
Open Accessindividual

GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial

This randomised, double-blind, placebo-controlled Phase IIb trial (n=81) found that a single-day inhaled synthetic mebufotenin treatment (GH001; 5-MeO-DMT) reduced depression symptoms more than placebo in adults with treatment-resistant depression, with remission in over half of those treated. No severe or serious adverse events were reported during the placebo-controlled period.

Published
Journal
JAMA Psychiatry
Authors
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Dueñas Herrero, R. M., Elices, M., Feeney, A., Gałuszko-Węgielnik, M., Jakuszkowiak-Wojten, K., Janů, L., Kelly, J. R., Ledden, K., Maclsaac, R., Madero, S., McInerney, S. J., Montejo, A. L., Nawka, A., Páleníček, T., Pérez Solà, V., Ramaekers, J. G., Reif, A., Ritter, P., Ryan, F., Svendsen, C. B., Sweeney, C., Terwey, T. H., Trivedi, M. H., Valcheva, V., Vieta, E., Thase, M. E.
Paywallmeta

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions A Systematic Review and Meta-Analysis

This meta-analysis (s=24) found that psychedelic-assisted therapy (s=8) was no more effective than open-label traditional antidepressants for treating major depression, and that, unlike traditional antidepressants (where blinding meaningfully influenced outcomes), PAT trials showed no difference between blinded and open-label conditions, confirming that PAT trials are effectively always unblinded.

Published
Journal
JAMA Psychiatry
Authors
Williams, Z. J., Barnett, H., Szigeti, B.
Open Accessindividual

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

In this triple‑blind, active placebo‑controlled randomised trial (n=144) of adults with treatment‑resistant depression, two 25 mg doses of psilocybin plus adjunct psychotherapy produced clinically meaningful reductions in depressive symptoms on exploratory secondary measures but did not significantly improve the pre‑second‑dose HAMD17 response rate versus nicotinamide.

Published
Journal
JAMA Psychiatry
Authors
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., Ströhle, A., Scharf, D., Spangemacher, M., Wolff, M., Assadi, Z., Bahri, S., Becher, L., Färber, L. V., Kirchen, N., Kulakova, E., Kunz, L., Meijer, A., Rohrmoser, B., Wellek, S., Berger, M. M., Gründer, G.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Quick Facts

Papers Indexed
27
h-Index
417
Open Access
No
Publisher
American Medical Association
Country
United States
Website
Visit